Free Newsletter
DC passes pharma rep licensing bill
Soon, pharma sales folk could be ticketed for repping without a license. The District of Columbia's governing council voted to require sales reps to obtain licenses, becoming the only jurisdiction in the country to do so.
The vote was close--seven to six. And the final measure lacked a provision that would have prohibited data-mining of doctors' prescribing habits. Nevertheless, the primary provision stands. Once licensed, reps could be suspended for fraudulent behavior.
- read the article in the Washington Post
- here's more from the Washington Business Journal
Related Articles:
DC to vote on rep-licensing bill. Report
Dr. Drug Rep tells all. Report
Top Lilly exec plays secret sales agent. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: